ArticleEuropean journal of medical research2025
Expression and prognostic value of estrogen-related receptor β alternative splicing isoforms in esophageal squamous cell carcinoma.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEstrogen-related receptor β (ERRβ) alternative splicing isoforms, including ERRβsf, ERRβ2, and ERRβΔ10, have been implicated in the pathogenesis of malignant tumors. Nevertheless, their specific impact on esophageal squamous cell carcinoma (ESCC) remains unclear. The study aimed to investigate the expression and prognostic value of ERRβ alternative splicing isoforms in ESCC.
methodsThis study prospectively collected ESCC tissues and paired normal tissues of 54 patients with ESCC who underwent esophagectomy without neoadjuvant therapy. The protein expression levels of ERRβ alternative splicing isoforms in ESCC and normal tissues were detected by Western blot. The Kaplan-Meier method with a log-rank test was used to estimate overall survival (OS). The Cox proportional hazards regression analysis was used to evaluate the independent prognostic factors.
resultsIn ESCC tissues, the ERRβsf/ERRβ ratio was significantly higher (P = 0.017) compared to paired normal tissues. Based on a cut-off value of 0.24, there were 18 and 36 cases in the high ERRβsf/ERRβ expression group and low ERRβsf/ERRβ expression group, respectively. Patients with high ERRβsf/ERRβ ratios had significantly better OS than those patients with low ERRβsf/ERRβ ratios (77.1% vs 50.8%, P = 0.024). The multivariate analysis revealed that ERRβsf/ERRβ (hazard ratio [HR] = 0.219, 95% confidence interval [CI] 0.063-0.767, P = 0.018) and N stage (HR = 7.892, 95% CI 1.328-46.911, P = 0.023) were independent prognostic factors for ESCC patients.
conclusionsThis study is the first to demonstrate the relationship between ERRβ alternative splicing isoforms in ESCC. A high ERRβsf/ERRβ ratio was associated with a better prognosis, indicating that ERRβ alternative splicing isoforms may serve as potential prognostic biomarkers for ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.